Maria-Victoria Mateos

MD, PhD
University Hospital of Salamanca, Spain

María-Victoria Mateos, MD, PhD is an Associate Professor and Consultant Physician at the Hematology Department of the University Hospital of Salamanca, Spain. www.usal.es

Dr Mateos received a medical degree from the University of Valladolid in Spain and completed her residency in Hematology at the University Hospital of Salamanca, where she also completed a doctoral degree (thesis: methylation of the p16 gene in multiple myeloma).

At the University Hospital of Salamanca, Dr Mateos is responsible for coordinating the Clinical Trials Unit. Dr. Mateos holds membership in several professional societies. She currently serves on the European Hematology Association (EHA) Scientific Program Committee and Advisory Board, as well as on the American Society of Hematology’s Scientific Committee on Plasma Cell Diseases. She is also a member of the Steering Committee for the Society of Hematologic Oncology, and she has been invited to join the ESH Scientific Committee. In 2015, Dr. Mateos was elected as a Councilor to the board of the EHA. She is also a member of the International Myeloma Working Group and the International Multiple Myeloma Society, and a member of the boards of both the Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA) and Spanish Myeloma Group (GEM).

An active researcher, Dr. Mateos has coordinated many clinical trials in elderly patients and patients with smoldering myeloma; her work has profoundly influenced current options for treating these patient populations. She has published over 150 papers in peer-reviewed international journals, some of which have become key references. Additionally, she is Associate Editor of myeloma in Annals of Hematology and a reviewer for several top journals, including the New England Journal of Medicine, Lancet, and Lancet Oncology. Among her invited presentations, Dr. Mateos contributed to the educational sessions of EHA 2012, ASH 2013, and ASCO 2015. Her areas of interest include multiple myeloma, the biology of plasma cells, and new drug development.